Suchergebnisse - (Person:"De Meyer, Sandra")

PubPharm (15)

1

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies

enthalten in: Journal of hepatology | 2015

von Lenz, O. | Verbinnen, T. | Fevery, B. | +8

2

Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir

enthalten in: Antimicrobial agents and chemotherapy | 2015

von Susser, S. | Flinders, M. | Reesink, H. | +7

3

Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients : REALIZE study

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2015

von Berg, T. | Andreone, P. | Pol, S. | +13

4

Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study

enthalten in: The Journal of infectious diseases | 2014

von Dierynck, I. | Thys, K. | Ghys, A. | +5

5

Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir

enthalten in: Virology journal | 2014

von De Meyer, S. | Ghys, A. | Dierynck, I. | +3

6

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C

enthalten in: Gastroenterology | 2014

von Buti, M. | Agarwal, K. | Horsmans, Y. | +13

7

Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4 : a randomized trial

enthalten in: The Journal of infectious diseases | 2013

von Benhamou, Y. | Moussalli, J. | Ratziu, V. | +7

CommentIn: J Infect Dis. 2014 Dec 1;210(11):1855-6. - PMID 24970848

8

Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2013

von Sullivan, J. | De Meyer, S. | Bartels, D. | +14

9

Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure

enthalten in: Journal of hepatology | 2013

von Pol, S. | Aerssens, J. | Zeuzem, S. | +14

CommentIn: J Hepatol. 2013 May;58(5):847-9. - PMID 23416431

10

Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure

enthalten in: Journal of hepatology | 2013

von Foster, G. | Zeuzem, S. | Andreone, P. | +12

CommentIn: J Hepatol. 2013 Jun;58(6):1259. - PMID 23376359